BACKGROUND: Cyclin E is an important regulator of cell-cycle progression. High levels of cyclin E protein in @entity0 have been reported in association with higher disease stage, poor histological differentiation of @entity5 , and lack of @entity134 receptors. Data concerning the prognostic relevance of cyclin E expression in @entity0 are conflicting. The aim of this retrospective study was to evaluate the prognostic relevance of cyclin E expression assessed by immunohistochemistry in @entity1 with operable @entity0 . MATERIAL/METHODS: The expression of cyclin E was analyzed by immunostaining in 174 @entity1 with @entity0 after radical mastectomy with a median follow-up period of 58 months. Tumor samples were judged to be negative (<2%) or positive (> or =2%) according to the percentage of cells showing the nuclear staining pattern. Ninety-nine (56.9%) @entity5 samples were regarded as cyclin E-positive. RESULTS: Positive staining for cyclin E determined poor prognosis compared with cyclin E-negative @entity1 in all cases (five-year cancer-specific survival rate of 64.5 vs. 84.5%, p=0.005), in the node-positive group (50.9 vs. 82.1%, p=0.008), and in @entity1 treated with adjuvant chemotherapy (71.0 vs. 96.6%, p=0.008). In a multivariate analysis, high expression of cyclin E was associated with a higher risk of @entity204 in the node-positive group (hazard ratio: 3.2, 95%CI: 1.3-8.2, p=0.015). CONCLUSIONS: It was demonstrated that a high expression of cyclin E measured by immunohistochemistry was a significant factor of poor prognosis, especially in the node-positive group.

Prognostic relevance of cyclin E expression in operable XXXX .

@entity1 :: ('9606', 'Species') :: ['women', 'patients'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer', 'invasive ductal breast cancer'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death']
@entity0 :: (MESH:D001943,Disease) :: ['breast cancer']
